How Could US Psychedelic Regulation Changes Impact the UK Life Sciences and Healthcare Sectors?
On 18 April 2026, President Trump signed the Executive Order ‘Accelerating medical treatments for serious mental illness’, which directs federal agencies to speed up research, regulatory review, and access pathways for psychedelic therapies. Brevia Health has examined the scope of the Executive Order, the potential timeline of these developments and how this could impact the UK.
